Engflag

Lad

Quick links to important sections

Lad

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lad

Property Description
Active Ingredient Loratadine (INN)
Form Tablet, oral solution, syrup
Pharmacological Class Second-Generation Antihistamine
Origin Synthetic compound (Tricyclic Piperidine derivative)
Common Use Symptomatic management of common allergies

What Type of Medicine is Lad (Loratadine)?

Lad is a single-ingredient product featuring the active substance Loratadine, which is chemically defined as a synthetic compound and classified as a second-generation antihistamine. This medication is administered orally and is available in forms such as the tablet, oral solution, and syrup.

Loratadine is designated as a tricyclic piperidine derivative, which places it within the class of peripheral H₁-blockers. Its unique formulation ensures that the medicine functions as a non-sedating antihistamine by exhibiting high selectivity for peripheral receptors, meaning it acts predominantly on receptors outside the central nervous system. This characteristic allows for the management of allergic symptoms without the significant sedation often associated with older antihistamines.

How Does Loratadine Work to Provide Relief?

Loratadine’s general function is to provide sustained relief by counteracting the effects of the natural chemical histamine, which the body releases during an allergic reaction. The compound achieves this through histamine receptor blockade, where it acts as a selective inverse agonist to bind to and block the activity of H₁-receptors. This mechanism is utilized for the symptomatic management of allergic conditions.

The overall purpose of Loratadine is to mitigate the systemic impact of allergic activities, for example, helping to ease discomfort during typical seasonal pollen periods. Loratadine is characterized by a long-acting duration of action, which supports its use as a single dose per day. This sustained effect means the medicine is designed to continuously block the receptors responsible for generating allergic symptoms over approximately 24 hours.

Regulatory References

  1. MedlinePlus Drug Information
  2. DrugBank Monograph

What side effects are possible with Lad?

Adverse events associated with Lad are generally categorized into common and serious reactions, with the overall safety profile monitored by government authorities such as the FDA and DEA.

Adverse Reaction Profile

Adverse reactions are documented across various System Organ Classes (SOC) and may include:

  • Common Reactions: Short-term physical effects reported include increased heart rate and blood pressure, dry mouth, loss of appetite, sweating, and tremors. Mental and sensory alterations are frequently reported.
  • Serious and Clinically Significant Reactions: Regulatory bodies classify serious adverse events as those resulting in outcomes such as death, life-threatening events, or persistent/significant disability. Specific serious risks associated with the substance may include the potential for long-term psychosis, the development of Hallucinogen Persisting Perception Disorder (HPPD) (known as “flashbacks”), and potential for severe acute anxiety, panic attacks, or psychosis.

Safety Considerations and Restrictions

Safety Class/Population Key Consideration or Restriction
Regulatory Status Classified as a Schedule I Controlled Substance by the DEA, indicating high potential for abuse and lack of accepted safety for medical use under supervision.
Exposure/Dose Pattern Tolerance to the drug's effects can develop quickly, requiring higher doses for the same effects, which may increase the unpredictability of risks.
Population-Specific Caution is advised for individuals with a history of pre-existing psychiatric conditions due to the potential to trigger or exacerbate conditions like anxiety or schizophrenia.
Monitoring Post-marketing surveillance is mandatory, requiring sponsors to report all unexpected serious suspected adverse reactions to the FDA for ongoing risk evaluation.

All safety information is strictly derived from official governmental regulatory documents and surveillance programs.

Overdose and Emergency Response

Lad Overdose and when to seek help

In the event of a suspected overdose with this medication, it is officially required to seek immediate medical help or contact a Poison Control Center right away. Urgent intervention is mandated due to the risk of documented acute manifestations reported in regulatory data.

Official Overdose Presentations and Management:

  • Adult Manifestations: Overdoses have been associated with reports of somnolence (drowsiness), tachycardia (fast heart rate), and headache. Overdosage also increases the occurrence of anticholinergic symptoms.
  • Pediatric Manifestations: In children, overdose cases with the syrup formulation have specifically included reports of palpitations and extrapyramidal signs, which differs from adult manifestations.
  • Antidote Status: Regulatory documents state that no specific antidote is known for this overdose.
  • Supportive Measures: Treatment consists of general symptomatic and supportive measures that must be instituted promptly and maintained for as long as necessary. Procedural steps that may be considered include the administration of activated charcoal as a slurry with water and gastric lavage.
  • Monitoring and Exclusion: Medical monitoring of the patient is required to be continued after emergency treatment. The drug is confirmed to be not removed by haemodialysis.

The official profile defines this as an urgent situation requiring rapid medical attention based on the documented clinical signs. Management relies exclusively on supportive care and observation, underscoring the necessity of continuous medical supervision after the initial emergency actions are performed.

Therapeutic Uses of Lad

What Lad Treats: Main Uses and Benefits

This medication is commonly used to help with symptoms caused by common allergies, which serves as its primary therapeutic application.

Loratadine is commonly used to help with the symptomatic management of conditions characterized by periods of heightened symptoms, such as Allergic Rhinitis (hay fever), which includes both seasonal and recurrent year-round manifestations, as well as allergic skin conditions like Urticaria (hives). It helps address symptom clusters related to heightened physiological activity, including persistent sneezing, rhinorrhea (runny nose), itching of the eyes or palate, and intense skin pruritus. This medication provides support that helps ease the overall symptom burden during difficult episodes.

This continuous effect contributes to improved comfort and assists with maintaining functional stability by helping to mitigate the symptoms that interfere with daily functioning, making it relevant in contexts involving heightened systemic burden. The medication's role in managing symptoms over a prolonged period further supports patients. Loratadine is considered relevant for managing symptoms related to inflammatory or irritative states, such as intense pruritus (itching) associated with both nasal allergies and chronic skin conditions like hives.

Quick Fact: Symptomatic Focus on Pruritus (Itching) Loratadine may assist with managing symptoms related to inflammatory or irritative states, such as intense pruritus (itching) associated with both nasal allergies and chronic skin conditions like hives.

Regulatory References

  1. NIH MedlinePlus overview on Loratadine

Eligibility and Restrictions for Use

Who can and cannot use Lad?

Official regulatory labeling dictates specific eligibility rules for Loratadine (Lad) based on age, physiological status, and existing conditions.

Contraindications (Must Not Use)

Category Restriction
Hypersensitivity Patients with known allergy to loratadine or any of the formulation's excipients (inactive ingredients).
Pediatric Age Children younger than 2 years of age, as safety and efficacy have not been established by regulatory authorities.
Hereditary Disorders Individuals with specific hereditary problems, such as galactose intolerance or total lactase deficiency, must avoid corresponding formulations (e.g., lactose-containing tablets).

Restricted and Conditional Use

Population Eligibility Status (Regulatory)
Pregnancy/Lactation Not recommended; use should be avoided as a precautionary measure during pregnancy and breastfeeding [Source 2.2].
Severe Organ Impairment Use is conditional and requires caution for patients with severe hepatic impairment or severe renal impairment (GFR < 30 mL/min), due to reduced drug clearance [Source 1.2, 2.4].
Age Groups The medicine is approved for use in Adults, Adolescents, and Children 2 years of age and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Lad emphasizes drug interactions that alter its concentration in the body, primarily by affecting its metabolism and transport. Healthcare providers must consider these constraints when prescribing.

Interacting Product Categories and Required Action

The most clinically significant interactions are defined by the co-administration of products that affect the enzymes responsible for Lad's breakdown (CYP3A4, CYP2C9) and its cellular transport (P-glycoprotein or P-gp).

Interacting Product Category Interaction Implication and Restriction
Strong CYP3A4 Inducers Co-administration is generally avoided or contraindicated due to the significant risk of drastically reducing Lad's exposure.
Strong or Moderate CYP3A4 Inhibitors Requires close monitoring due to the potential for increased Lad exposure.
CYP2C9 Inhibitors and Inducers Requires close monitoring due to the potential for altered Lad exposure.
P-glycoprotein (P-gp) Inhibitors Requires close monitoring due to the potential for altered Lad exposure.
Food Products Administration must follow specific instructions relative to food for proper absorption and consistent effect.

These constraints define the official interaction profile, guiding the use of Lad to ensure that its concentration remains within the intended therapeutic window. The severity classification ranges from combinations that are prohibited to those requiring caution and close observation.

Mechanism of Action

Lad, chemically d-lysergic acid diethylamide (LSD), primarily targets the serotonergic system in the central nervous system. Its main interaction is with the 5-HT2A receptor, where it functions as a partial agonist. This receptor is a G-protein coupled receptor (GPCR) that, upon activation, typically couples to the Gq protein. Agonism at 5-HT2A receptors, particularly those located on cortical pyramidal neurons, triggers an intracellular cascade involving the activation of phospholipase C (PLC), leading to the hydrolysis of PIP2 ( phosphatidylinositol 4,5-bisphosphate) into IP3 (inositol triphosphate) and DAG (diacylglycerol). The increase in IP3 concentration facilitates the release of intracellular calcium ions ( Ca^2+) from the endoplasmic reticulum. Downstream, this modulates neuronal excitability and synaptic transmission, especially in circuits involved in sensory perception and cognition, such as the prefrontal cortex and the default mode network. System-level consequences include a reduction in oscillatory power within the default mode network and altered functional connectivity between various brain regions. Lad also acts as an agonist at the 5-HT1A receptor and modulates dopaminergic D2 receptors and TAAR1 (Trace Amine-Associated Receptor 1), contributing to its pleiotropic systemic physiological effects, including sympathetic nervous system stimulation (e.g., increased heart rate and blood pressure).

Dosage and Administration Information

How to Use Loratadine (Lad)

Loratadine is an oral medication with a once-daily administration schedule. The medication is available in several oral dosage forms, including tablets, oral solutions/syrups, and orally disintegrating tablets (ODTs). The standard administration route is consistent across all approved uses.

Labeled Dosing Regimens

The most common dose for adults and children aged 6 years and older (or those over 30 kg) is 10 mg taken once a day. For younger children, specifically those aged 2 to 5 years (or less than or equal to 30 kg), the approved dose is typically 5 mg once daily, often administered using the oral solution or syrup. The maximum recommended dose for adults is strictly 10 mg per 24 hours.

Administration Conditions and Adjustments

Loratadine may be taken with or without food, providing flexibility in its daily timing. The long duration of action is intended to provide a continuous effect over 24 hours. If using the oral solution or syrup, it must be measured with a calibrated dosing device to ensure accurate intake.

Specific dose modifications are mandated for patients with reduced drug clearance. For those with severe hepatic impairment or severe renal impairment (creatinine clearance less than or equal to 30 mL/min), the standard regimen for these cases involves a reduced initial dose of 10 mg every other day. For older adults, no routine dose change is specified based on age alone.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lad (Loratadine)

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research has primarily explored the application of Lad in the context of conditions characterized by fluctuating or episodic manifestations, such as seasonal and year-around allergic rhinitis (hay fever). The evidence base largely relies on Randomized Controlled Trials (RCTs), where the medicine was evaluated in specific groups of people against either an inactive substance (placebo) or other established treatments.

Studies monitored how symptoms change over time, including measurements of sneezing, rhinorrhea (runny nose), and itching in the eyes and palate. Findings describe patterns observed in the studies where measured changes in symptom scores data show patterns related to the administration of Lad. Comparative evidence is lacking for certain direct head-to-head comparisons against all established treatments.

Evidence for Use in Urticaria (Hives) and Allergic Skin Conditions

Lad was evaluated in the context of conditions associated with acute or disruptive episodes, specifically chronic urticaria (hives). Controlled trials monitored patient-reported outcomes describing perceived discomfort, primarily focusing on the intensity of pruritus (itching) and the size and number of wheals.

Research provides insight into short-term changes where the measurements of itching intensity may relate to patient-reported outcomes describing perceived discomfort. The existing research provides limited insight into the application of Lad for rare forms of skin allergies, as the research primarily focused on Chronic Idiopathic Urticaria.

Long-Term Follow-up and Study Gaps

Clinical research into Lad has mainly explored short-term symptom changes. Studies report how symptoms evolved in the observed populations over a 24-hour period, a duration studied in the trials. However, the data for certain groups remain insufficient when looking at continuous usage for extended periods (such as a year or more). This means the full long-term outcomes are not fully established, particularly concerning continuous use over multiple seasons.

Research does not determine whether an individual will respond similarly; study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Loratadine: MedlinePlus Drug Information (General overview and use in special populations)

Frequently Asked Questions (FAQ)

Common questions about Lad (FAQ)

Q: What is Lad (Labetalol) and how does it work?

A: Lad (Labetalol) is a beta-blocker medication used to treat high blood pressure (hypertension). It works by blocking both alpha and beta adrenergic receptors. By blocking these receptors, Lad helps to slow the heart rate and relax blood vessels, which allows blood to flow more easily and lowers blood pressure. It is often used in situations where a quick reduction in blood pressure is necessary, such as a hypertensive emergency.

Q: How should I take Lad?

A: Lad is available as an oral tablet and an injectable solution. The tablets are typically taken with food to enhance absorption. Your healthcare provider will determine the correct dose and schedule for you based on your condition and response to treatment. For the tablets, it's important to take them exactly as prescribed and not to stop taking them abruptly, as this can lead to serious heart problems. If you miss a dose, take it as soon as you remember, unless it is close to the time for your next dose.

Q: What are the common side effects of Lad?

A: Common side effects of Lad may include dizziness, tiredness, nausea, stuffy nose, and tingling of the scalp. These side effects are usually mild and may lessen as your body adjusts to the medication. If these or any other side effects persist or become bothersome, you should contact your healthcare provider.

Q: What should I avoid while taking Lad?

A: While taking Lad, you should avoid sudden changes in position (like standing up too quickly) as this can worsen dizziness and increase the risk of fainting. You should also limit or avoid alcohol as it can increase the blood pressure lowering effect and worsen side effects. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking, as some can interact with Lad.

How should Lad be stored and disposed of?

How to Store and Dispose of Lad (Loratadine)

Loratadine must be stored under specific conditions to maintain product stability, as defined by regulatory labeling.

Required Storage and Protection

  • Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) .
  • Container: Keep the medication in its original container with the lid tightly closed .
  • Protection: The oral solution/syrup form must not be frozen , and all forms should be protected from excess heat and moisture .
  • Child Safety: Store the medicine out of the reach and sight of children .

Official Disposal Instructions

Unused or expired Loratadine must be disposed of according to local regulatory requirements . The medication must not be discarded in household waste or wastewater . Consult a pharmacist for guidance on proper disposal methods .

: DailyMed, National Library of Medicine. Claritin (loratadine) tablet. : NIH MedlinePlus. Loratadine. : NIH MedlinePlus. Loratadine. : NIH MedlinePlus. Loratadine. : NIH MedlinePlus. Loratadine. : Electronic Medicines Compendium (emc), Summary of Product Characteristics for Clarityn 10 mg Tablets. : Electronic Medicines Compendium (emc), Summary of Product Characteristics for Clarityn 10 mg Tablets. : NIH MedlinePlus. Loratadine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lad found in:

A-Z Index: